Progenesis

Executive Summary

Progenesis is a US-based reproductive genetics company offering advanced preimplantation genetic testing (PGT) services, including PGT-A, PGT-M, and PGT-SR, along with the Revela® portal for case management. Founded in 2004 and headquartered in Boston, the company aims to democratize access to reproductive genetics by supporting IVF clinics and fertility care communities through testing, education, and collaboration. As the IVF market grows globally, Progenesis is well-positioned to capture demand for comprehensive genetic testing that improves embryo selection and reduces the risk of genetic disorders. Despite strong industry tailwinds, Progenesis faces competition from established players like CooperSurgical and Natera, as well as emerging direct-to-consumer models. The company's private status limits visibility into financial performance and pipeline progress, but its longevity suggests operational resilience. Key growth drivers include expanding test menu, forging partnerships with large IVF networks, and leveraging digital platforms to enhance client experience. Upcoming catalysts, if realized, could strengthen its market share and attract strategic interest.

Upcoming Catalysts (preview)

• Q3 2026Launch of Expanded PGT Panel (e.g., PGT-A Plus with Mitochondrial DNA Assessment)65% success
• Q2 2027Strategic Partnership with Major IVF Clinic Network (e.g., 50+ clinics)55% success
• Q1 2027Expansion into Canadian or European Reproductive Genetics Market45% success